- Conditions
- Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
- Interventions
- Placebo Medication, Metformin
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 902
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- placebo, Exenatide LAR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 7
- States / cities
- Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- ALS (Amyotrophic Lateral Sclerosis)
- Interventions
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
- Biological · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Eosinophilic Esophagitis
- Interventions
- CC-93538, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Oakland, California • San Diego, California + 23 more
- Conditions
- Type 1 Diabetes
- Interventions
- Ergocalciferol, Placebo
- Drug · Other
- Lead sponsor
- Benjamin U. Nwosu, MD
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Exenatide, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes (T2D)
- Interventions
- NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Anti-IP-10 Antibody
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SRP-4045, Placebo
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 21 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
- Conditions
- Disorders of Gut-brain Interaction
- Interventions
- Active Therapeutic acupuncture intervention, Sham therapeutic acupuncture treatment
- Other
- Lead sponsor
- Children's Hospital of Orange County
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Obesity, Overweight
- Interventions
- VRB-101, Placebo
- Drug
- Lead sponsor
- Verdiva Bio Dev Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 18 more
- Conditions
- Obesity, Cardiovascular Diseases
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,946 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Covina, California • Fresno, California + 39 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Morehead City, North Carolina • El Paso, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Buparlisib, Buparlisib matching Placebo, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- Fayetteville, Arkansas • Boston, Massachusetts • St Louis, Missouri + 4 more
- Conditions
- Obesity, Overweight, Obstructive Sleep Apnoea
- Interventions
- NNC0487-0111, Placebo (matched to NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
- Conditions
- Type I Diabetes
- Interventions
- NNC0361-0041, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 16
- States / cities
- Orange, California • San Francisco, California • Stanford, California + 13 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Sun City, Arizona • Covina, California + 30 more
- Conditions
- Bladder Cancer
- Interventions
- HS-410, Placebo, BCG
- Biological
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide once weekly, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 14,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
- Conditions
- Obesity
- Interventions
- semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 407 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 61
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more